載入...
Expanding Patient Access to Investigational Drugs: Single Patient Investigational New Drug and the “Right to Try”
With drug approval times taking an average of 8 years from entry into clinical trials to full U.S. Food and Drug Administration (FDA) approval, patients with life-threatening and severely debilitating disease and no reasonable therapeutic options are advocating for expanded access (EA) to investigat...
Na minha lista:
| 發表在: | JACC Basic Transl Sci |
|---|---|
| 主要作者: | |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Elsevier
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6059004/ https://ncbi.nlm.nih.gov/pubmed/30062214 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jacbts.2017.11.007 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|